United Therapeutics Corp - Company Profile
Powered by 
All the data and insights you need on United Therapeutics Corp in one report.
$295
- Save hours of research time and resources with
our up-to-date United Therapeutics Corp Strategy Report
- Understand United Therapeutics Corp position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
United Therapeutics Corp (United Therapeutics) develops and commercializes innovative pharmaceutical products for the treatment of cardiovascular disorders, particularly pulmonary arterial hypertension, and infectious diseases. The company's products consist of prostacyclin analogs including Remodulin (treprostinil) injection; Tyvaso (treprostinil) inhalation solution; and Orenitram (treprostinil). Adcirca (tadalafil) is a phosphodiesterase type 5 (PDE-5) inhibitor and Unituxin (dinutuximab), a monoclonal antibody for oncologic applications, are the other products. Its product candidates include monoclonal antibodies (mAbs), glycobiology antiviral agents, and cell-based therapies. The company also develops engineered lungs for transplantation in the pre-clinical stage. It manufactures products in its facility in Silver Spring, Maryland. It markets its products in the US, Europe, South America, and Israel. United Therapeutics is headquartered in Silver Spring, Maryland, the US.
Headquarters
United States of America
Address
1000 Spring St, Silver Spring, Maryland, 20910
Website
www.unither.com
Telephone
1 301 6089292
No of Employees
1,168
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
UTHR (NASD)
Revenue (2022)
$2.3B
20.2%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
35.4%
(2022 vs 2021)
Market Cap*
$11.1B
Net Profit Margin (2022)
XYZ
12.7%
(2022 vs 2021)
* As of and is in US$
United Therapeutics Corp premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| - | Adcirca |
| Marketed: | Tyvaso |
| Remodulin Injection | Remunity |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Acquisitions/Mergers/Takeovers | In December, the company acquired Miromatrix Medical Inc. |
| 2023 | Acquisitions/Mergers/Takeovers | In October, the company acquired IVIVA Medical, Inc. |
| 2023 | Corporate Changes/Expansions | In June, the company unveiled its new net zero energy distribution center in North Carolina, the US. |
Competitor Comparison
| Key Parameters | United Therapeutics Corp | GSK plc | Gilead Sciences Inc | FibroGen Inc | Acceleron Pharma Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United Kingdom | United States of America | United States of America | United States of America |
| City | Silver Spring | Brentford | Foster City | San Francisco | Cambridge |
| State/Province | Maryland | England | California | California | Massachusetts |
| No. of Employees | 1,168 | 70,212 | 18,000 | 486 | 312 |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Martine A. Rothblatt, Ph.D. | Chief Executive Officer; Chairman | Executive Board | 2015 | 68 |
| James C. Edgemond | Treasurer; Chief Financial Officer | Senior Management | 2015 | 55 |
| Michael Benkowitz | Chief Operating Officer; President | Senior Management | 2016 | 51 |
| Paul A. Mahon | General Counsel; Executive Vice President; Secretary - Corporate | Senior Management | 2003 | 59 |
| Ray Kurzweil | Director | Non Executive Board | 2002 | 75 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward